| Literature DB >> 29957236 |
Maciej Banach1, Angelo Maria Patti2, Rosaria Vincenza Giglio2, Arrigo F G Cicero3, Atanas G Atanasov4, Gani Bajraktari5, Eric Bruckert6, Olivier Descamps7, Dragan M Djuric8, Marat Ezhov9, Zlatko Fras10, Stephan von Haehling11, Niki Katsiki12, Michel Langlois13, Gustavs Latkovskis14, G B John Mancini15, Dimitri P Mikhailidis16, Olena Mitchenko17, Patrick M Moriarty18, Paul Muntner19, Dragana Nikolic2, Demosthenes B Panagiotakos20, Gyorgy Paragh21, Bernhard Paulweber22, Daniel Pella23, Christos Pitsavos24, Željko Reiner25, Giuseppe M C Rosano26, Robert S Rosenson27, Jacek Rysz28, Amirhossein Sahebkar29, Maria-Corina Serban30, Dragos Vinereanu31, Michal Vrablík32, Gerald F Watts33, Nathan D Wong34, Manfredi Rizzo2.
Abstract
Statins are the most common drugs administered for patients with cardiovascular disease. However, due to statin-associated muscle symptoms, adherence to statin therapy is challenging in clinical practice. Certain nutraceuticals, such as red yeast rice, bergamot, berberine, artichoke, soluble fiber, and plant sterols and stanols alone or in combination with each other, as well as with ezetimibe, might be considered as an alternative or add-on therapy to statins, although there is still insufficient evidence available with respect to long-term safety and effectiveness on cardiovascular disease prevention and treatment. These nutraceuticals could exert significant lipid-lowering activity and might present multiple non-lipid-lowering actions, including improvement of endothelial dysfunction and arterial stiffness, as well as anti-inflammatory and antioxidative properties. The aim of this expert opinion paper is to provide the first attempt at recommendation on the management of statin intolerance through the use of nutraceuticals with particular attention on those with effective low-density lipoprotein cholesterol reduction.Entities:
Keywords: cardiovascular risk; dyslipidemia; nutraceuticals; position paper; statin intolerance
Mesh:
Substances:
Year: 2018 PMID: 29957236 DOI: 10.1016/j.jacc.2018.04.040
Source DB: PubMed Journal: J Am Coll Cardiol ISSN: 0735-1097 Impact factor: 24.094